Related Experiment Video
Updated: Jun 6, 2026

A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics
Published on: September 16, 2022
The problem of complicated skin and skin structure infections: the need for new agents
1Harvard Medical School and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. rmoeller@bidmc.harvard.edu
Abstract:
Complicated skin and skin structure infections (cSSSIs) continue to pose a significant clinical challenge. The most frequent cause of these infections is Staphylococcus aureus, although other organisms, including Streptococcus pyogenes and, in certain circumstances, Enterobacteriaceae, are also involved. The relentless increase in methicillin resistance among S. aureus isolated in hospitals throughout the world has made it important to provide coverage for these organisms when treating cSSSIs in hospitals. More recently, however, there has been a striking increase in methicillin resistance among staphylococci isolated from infections acquired in the community, particularly in the USA. As a result, previous recommendations for empirical therapy of these important infections are now outdated. The papers in this Supplement detail the properties of a new broad-spectrum cephalosporin that has activity against MRSA and is, thus, an outstanding candidate for empirical therapy of cSSSIs. The papers included provide data on the in vitro activity, pharmacokinetics and pharmacodynamics as well as the clinical efficacy of ceftaroline fosamil, which is a welcome addition to our therapeutic armamentarium against cSSSIs.
Insights
Complicated skin infections are a challenge due to rising antibiotic resistance. A new cephalosporin, ceftaroline fosamil, shows promise for treating these infections, including those caused by MRSA.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Complicated skin and skin structure infections (cSSSIs) present a significant clinical challenge.
- Staphylococcus aureus is a primary cause, with increasing methicillin resistance (MRSA) in both hospital and community settings.
- Existing empirical therapies for cSSSIs are becoming outdated due to rising antimicrobial resistance.
Purpose of the Study:
- To evaluate the properties and clinical efficacy of ceftaroline fosamil.
- To assess ceftaroline fosamil as a potential empirical therapy for cSSSIs, including MRSA infections.
Main Methods:
- In vitro activity assessment.
- Pharmacokinetic and pharmacodynamic profiling.
- Clinical efficacy trials.
Main Results:
- Ceftaroline fosamil demonstrates broad-spectrum activity, including against MRSA.
- Pharmacokinetic and pharmacodynamic data support its efficacy.
- Clinical studies confirm its effectiveness in treating cSSSIs.
Conclusions:
- Ceftaroline fosamil is a valuable new therapeutic option for cSSSIs.
- Its activity against MRSA makes it suitable for empirical treatment.
- This agent expands treatment options for challenging skin infections.
Related Concept Videos
Staphylococcal Skin Infections
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
The Skin Microbiota
Acne Infection
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Clinical Significance of Antibiotic Resistance
